论文部分内容阅读
目的探讨重组人血管内皮抑制素联合托泊替康治疗复发性卵巢癌的临床疗效。方法选取2014年3月—2016年1月中国人民解放军第273医院收治的复发性卵巢癌患者72例,随机分为对照组和治疗组,每组各36例。对照组患者静脉滴注注射用盐酸托泊替康,1.2 mg/m2加入生理盐水100 m L中,滴注30 min,连续用药5 d。治疗组在对照组治疗基础上静脉滴注重组人血管内皮抑素注射液,15 mg加入生理盐水500 m L,静脉滴注5 h,连续给药14 d。每21天为1个疗程,所有患者治疗2个疗程。观察两组的临床疗效,同时比较两组患者生活质量和毒副反应发生情况。结果治疗后,对照组总有效率30.56%,临床受益率为58.34%,治疗组总有效率为47.22%,临床受益率为77.78%,两组总有效率和临床收益率比较差异均具有统计学意义(P<0.05)。对照组和治疗组的生活质量改善率分别为36.11%、52.78%,两组比较差异有统计学意义(P<0.05)。与对照组比较,治疗组患者白细胞减少、贫血、血小板减少、恶心呕吐的发生率显著降低,两组比较差异有统计学意义(P<0.05),两组肝功能异常发生率比较差异无统计学意义。结论重组人血管内皮抑素联合托泊替康治疗复发性卵巢癌具有较好的临床疗效,可以改善患者的生活质量,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of recombinant human endostatin combined with topotecan in the treatment of recurrent ovarian cancer. Methods Seventy-two patients with recurrent ovarian cancer who were admitted to the 273 Hospital of Chinese People’s Liberation Army from March 2014 to January 2016 were randomly divided into control group and treatment group, with 36 cases in each group. Patients in the control group were given intravenous injection of topotecan hydrochloride and 1.2 mg / m2 of normal saline for 100 minutes. The treatment group was treated with intravenous drip of recombinant human endostatin injection on the basis of the control group, 15 mg of normal saline 500 m L, intravenous infusion of 5 h, continuous administration for 14 d. Every 21 days for a course of treatment, all patients treated 2 courses. The clinical efficacy of the two groups was observed, and the quality of life and the incidence of side effects were compared between the two groups. Results After treatment, the total effective rate of the control group was 30.56%, the clinical benefit rate was 58.34%, the total effective rate of the treatment group was 47.22%, the clinical benefit rate was 77.78%. There was statistical difference between the two groups in total effective rate and clinical rate of return Significance (P <0.05). The quality of life improvement of the control group and the treatment group were 36.11% and 52.78%, respectively, with significant difference between the two groups (P <0.05). Compared with the control group, the incidence of leukopenia, anemia, thrombocytopenia and nausea and vomiting in the treatment group was significantly lower than that in the control group (P <0.05). There was no significant difference in the incidence of liver dysfunction between the two groups significance. Conclusion Recombinant human endostatin combined with topotecan in the treatment of recurrent ovarian cancer has good clinical efficacy, can improve the quality of life of patients with a certain clinical application value.